[{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"IOV-3001","moa":"IL-2","graph1":"Oncology","graph2":"Preclinical","graph3":"Avid Bioservices","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Avid Bioservices \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Avid Bioservices \/ Iovance Biotherapeutics"},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Terra CoV-2 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avid Bioservices","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Avid Bioservices \/ Oragenics","highestDevelopmentStatusID":"1","companyTruncated":"Avid Bioservices \/ Oragenics"},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Mapp Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Human monoclonal antiviral antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Avid Bioservices","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Avid Bioservices \/ Avid Bioservices","highestDevelopmentStatusID":"5","companyTruncated":"Avid Bioservices \/ Avid Bioservices"},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Immunology","graph2":"Phase III","graph3":"Avid Bioservices","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Avid Bioservices \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Avid Bioservices \/ Humanigen"}]

Find Clinical Drug Pipeline Developments & Deals by Avid Bioservices

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : This collaboration enhances commercial production efforts for lenzilumab in advance of potential filings for emergency use authorization (EUA) and subsequent Biologics License Application (BLA) later this year.

                          Brand Name : Humaneered

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 03, 2021

                          Lead Product(s) : Lenzilumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Humanigen

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : Mapp Biopharmaceutical has contracted Avid to provide process transfer, scale-up and clinical manufacturing services to support one of its development programs for a novel antiviral drug candidate. Avid and Mapp will immediately commence the initial phas...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 26, 2020

                          Lead Product(s) : Human monoclonal antiviral antibody

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Recipient : Mapp Biopharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : Under terms of the agreement, Avid will provide Oragenics with analytical method development, process development and drug substance manufacturing services to support development of Oragenics’ novel SARS CoV-2 (COVID-19) spike protein vaccine candidate...

                          Brand Name : Terra CoV-2

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          August 20, 2020

                          Lead Product(s) : Terra CoV-2 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Oragenics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : Iovance Biotherapeutics has selected Avid to provide process development, pilot-batch manufacturing and CGMP manufacturing services to support development of IOV-3001, a novel antibody cytokine engrafted protein.

                          Brand Name : IOV-3001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 06, 2020

                          Lead Product(s) : IOV-3001

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Iovance Biotherapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank